Acorda Therapeutics
(NSDQ:ACOR) said today that the phase III clinical trial evaluating its inhaled formulation of Parkinson’s drug levodopa met its primary endpoint. The drug was studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms.
The randomized phase III trial enrolled 339 patients to evaluate the efficacy and safety of CVT-301 compared with a placebo in patients with Parkinson’s who experience motor fluctuations. Study participants self-administered the therapy up to 5 times per day for 12 weeks.
Get the full story at our sister site, Drug Delivery Business News.
The post Acorda’s inhaled Parkinson’s drug meets primary endpoint in Phase III trial appeared first on MassDevice.